Organization
University of Turin
4 clinical trials
9 abstracts
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Clinical trial
Study Protocol for Near-infrared Molecular Imaging for Lung Cancer Detection and Treatment During Mini-invasive Surgery (Phase II Trial) - (the RECOGNISE Study)Status: Recruiting, Estimated PCD: 2025-07-01
Abstract
Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval.Org: Department of Oncology, Ivrea Community Hospital, ASL-TO4, Ivrea (Turin), Italy, Department of Oncology, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy, Department of Oncology , University of Turin, A.O.Ordine Mauriziano, Turin, Italy, Department of Oncology, University of Turin, AO Ordine Mauriziano, Turin, Italy, Royal Marsden Hospital, Renal and Melanoma Unit, London, United Kingdom,
Clinical trial
Prospective Randomized Clinical Trial on Oral and Intravenous Antibiotic Prophylaxis in Colorectal Surgery (COLORAL1).Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
A Phase II, Open-Label, Single Arm, Prospective, Multicenter Study of Niraparib Plus Dostarlimab in Patients With Advanced NSCLC and/or MPM, and Positive for PD-L1 Expression and Germline or Somatic Mutations in the HRR GenesStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM)Status: Recruiting, Estimated PCD: 2025-01-03
Abstract
Preoperative assessment in lung-limited metastatic patients with colorectal cancer: The Meta-Lung Score.Org: University Hospital and University of Cagliari, Division of Thoracic Surgery at “A. Businco Cancer Center”, Division of Thoracic Surgery, Brigham and Women's Hospital, Cardiovascular and Thoracic Department, Città della Salute e della Scienza,
Abstract
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.Org: Università degli Studi di Milano, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, University of Turin, Candiolo Cancer Institute-FPO, IRCCS,
Abstract
Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Harvard University, Clinical Oncology Center, Polytechnic University of Marche,
Abstract
Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.Org: Pediatric Onco-Hematology Department, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza di Torino, University of Torino, Centre for Biostatistics, Epidemiology and Public Health,
Abstract
Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.Org: University of Brescia, ASST Spedali Civili - Brescia, University Hospital of Parma, University of Pisa, Pisa, Italy, ATC Innovation Lab,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,